Zenith Capital Corp. (ZHCLF)

Market Cap	1.61M -89.9%
Revenue (ttm)	n/a
Net Income	-9.14M
EPS	-0.06
Shares Out	161.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,300
Open	0.0100
Previous Close	n/a
Day's Range	0.0100 - 0.0100
52-Week Range	0.0003 - 0.2996
Beta	630.55
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 21, 2026

About Zenith Capital

Zenith Capital Corp., a biotechnology investment company, develops bromodomain (BET) inhibitors for the treatment of cancer and other disorders with unmet medical needs in Canada. The company’s lead compound ZEN-3694, which is in Phase 2b clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as for NUT carcinoma, solid tumors, breast and metastatic cancer, ovarian and colorectal cancer, lung and pancreatic cancer, and malignant peripheral nerve sheath tumors. It has collaborations with the National Cancer ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZHCLF

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 23, 2026

Data Sources Report a data error